[Skip to Content]
[Skip to Content Landing]
Article
November 20, 1991

Recombinant Interferon Gamma in Condylomata Acuminata

Author Affiliations

University-Hospital Eppendorf Hamburg, Germany for the Recombinant Interferon-Gamma in Condylomata Acuminata Study Group

University-Hospital Eppendorf Hamburg, Germany for the Recombinant Interferon-Gamma in Condylomata Acuminata Study Group

JAMA. 1991;266(19):2706. doi:10.1001/jama.1991.03470190054028
Abstract

To the Editor.  — Recent studies have shown that genital warts can be effectively treated with interferon administered intralesionally.1-3 This approach is not ideal since untreated lesions do not respond and pain at the injection site may limit the use of this route of administration to treat multiple lesions, which are a common clinical presentation of genital human papillomavirus infection.However, using a systemic approach, a recent international multicenter trial,4 which used subcutaneous injections of recombinant interferon alfa-2a in daily doses of 3.0 mIU or 9.0 mIU three times weekly for 4 weeks, failed to demonstrate the superiority of any of the two interferon groups over the placebo group (response rates of 34% or 25%, respectively, vs 30%).In contrast, low-dose treatment with 1.5 mIU of recombinant interferon alfa-2a, which was given cyclically (daily therapy for consecutive days followed by a therapy-free interval of 4 weeks), seemed to

×